The previous European Guidelines on CVD prevention in clinical practice were published in 2016. Recent developments in prediction of cardiovascular disease (CVD) risk and treatment benefit, as well as novel treatments and treatment goals, necessitated new, up-to-date guidelines.
What is the Joint Task Force of the European Society of Cardiology?
The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012).
What are the current guidelines on ASCVD prevention?
The current guidelines provide recommendations on ASCVD prevention to support shared decision-making by the patient and their healthcare professional based on individual patient characteristics. Special considerations have been given to differences in age, sex and gender, life expectancy, risk factor profiles, ethnic, and geographic differences.
What are the European Joint Task Force guidelines for cardiovascular disease prevention?
The present guidelines represent an evidence-based consensus of the 6th EuropeanJoint Task Force involving 10 professional societies. By appraising the current evidence and identifying remaining knowledge gaps inmanaging CVD prevention, the Task Force formulated recommendations to guideactions to prevent CVD in clinical practice.
Can I use the European Society of Cardiology (ESC) guidelines?
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC.
What is cardiovascular disease prevention (CVD)?
Cardiovascular disease (CVD) prevention is defined as a coordinated set ofactions, at the population level or targeted at an individual, that are aimed ateliminating or minimizing the impact of CVDs and their relateddisabilities. 1 CVD remains a leading cause of morbidity and mortality, despite improvements inoutcomes.
